Climb Bio, Inc. (CLYM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Climb Bio reported revenue of $0. Net income was -$59.9M, or -$0.88 per diluted share. Operating activities generated -$54.4M of cash, leaving -$54.5M of free cash flow. At fiscal year end, Climb Bio held $167.7M in total assets against $7.3M in total liabilities, including $35.7M of cash and equivalents.
Open the full interactive Climb Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Climb Bio Key Stats
| Share Price | $10.31 |
|---|---|
| Market Cap | $785.1M |
| 52-Week Range | $1.64 – $17.84 |
| Shares Outstanding | 76.2 million (basic, 2026 Q2) |
Climb Bio Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$35.7M | -$45.1M | -$40.3M | -$82.0M | -$67.9M |
| Pre-Tax Income | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| Diluted EPS | -$4.24 | -$1.72 | -$1.30 | -$1.53 | -$0.88 |
Climb Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$12.9M | -$17.5M | -$13.7M | -$13.5M |
| Diluted EPS | -$0.19 | -$0.26 | -$0.20 | -$0.18 |
Climb Bio Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $46.9M | $43.6M | $93.1M | $87.2M | $35.7M |
| Current Assets | $148.3M | $134.4M | $110.3M | $154.9M | $105.8M |
| Total Assets | $173.2M | $135.0M | $110.5M | $217.2M | $167.7M |
| Current Liabilities | $6.0M | $6.1M | $2.8M | $4.9M | $7.0M |
| Total Liabilities | $6.0M | $6.3M | $2.9M | $5.3M | $7.3M |
| Shareholders' Equity | $167.2M | $128.7M | $107.6M | $211.9M | $160.5M |
Climb Bio Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.4M |
| Cash From Investing | -$115.0M | $34.4M | $69.0M | -$121.1M | $2.8M |
| Cash From Financing | $177.2M | $0 | $841,000 | $130.7M | -$21,000 |
| Free Cash Flow | — | — | — | -$20.2M | -$54.5M |
Figures from Climb Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Climb Bio financials page for every line item.
Climb Bio Company Profile
| Ticker | CLYM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Wellesley Hills, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001768446 |
Frequently Asked Questions
What was Climb Bio's revenue in fiscal 2025?
Climb Bio (CLYM) reported revenue of $0 for fiscal 2025.
What is Climb Bio's annual revenue history?
Climb Bio's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Climb Bio's net income in fiscal 2025?
Climb Bio reported net income of -$59.9M for fiscal 2025.
What was Climb Bio's earnings per share (EPS) in fiscal 2025?
Climb Bio's diluted EPS was -$0.88 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Climb Bio generate in fiscal 2025?
Climb Bio generated -$54.5M of free cash flow in fiscal 2025.
What was Climb Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Climb Bio reported revenue of $0.
How many shares of Climb Bio are outstanding?
Climb Bio reported a weighted average of 76.2 million basic shares outstanding in 2026 Q2.
What is Climb Bio's market cap?
Based on its latest closing price, Climb Bio (CLYM) has a market capitalization of about $785.1M.
When does Climb Bio's fiscal year end?
Climb Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Climb Bio headquartered?
Climb Bio lists its business address in Wellesley Hills, Massachusetts in its SEC filings.